Trial record 1 of 1 for:    1230.14
Previous Study | Return to List | Next Study

Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Boehringer Ingelheim
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01721876
First received: November 2, 2012
Last updated: July 9, 2014
Last verified: July 2014

November 2, 2012
July 9, 2014
January 2013
January 2016   (final data collection date for primary outcome measure)
  • Complete Remission (CR) [ Time Frame: 4 years ] [ Designated as safety issue: No ]
  • Complete remission with incomplete blood count recovery (CRi) [ Time Frame: 4 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01721876 on ClinicalTrials.gov Archive Site
  • Overall survival (OS) [ Time Frame: 4 years ] [ Designated as safety issue: No ]
  • Event-free survival (EFS) [ Time Frame: 4 years ] [ Designated as safety issue: No ]
  • Relapse-free survival (RFS) [ Time Frame: 4 years ] [ Designated as safety issue: No ]
  • Overall survival (OS) [ Time Frame: 4 years ] [ Designated as safety issue: No ]
  • Event-free survival (EFS) [ Time Frame: 4 years ]
  • Relapse-free survival (RFS) [ Time Frame: 4 years ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)
A Phase III Randomised, Double-blind, Controlled, Parallel Group Study of Intravenous Volasertib in Combination With Subcutaneous Low-dose Cytarabine vs. Placebo + Low-dose Cytarabine in Patients >=65 Years With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy

To investigate the efficacy, safety, and pharmacokinetics of intravenous volasertib + subcutaneous low dose cytarabine in patients >= 65 years of age with previously untreated acute myeloid leukaemia, ineligible for intensive remission induction therapy

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Leukemia, Myeloid, Acute
  • Drug: placebo
    comparator
  • Drug: volasertib
    'Investigational Medicinal Product
  • Drug: low dose cytarabine
    background medication
  • Experimental: Volasertib + low dose cytarabine
    Interventions:
    • Drug: volasertib
    • Drug: low dose cytarabine
  • Placebo Comparator: PLACEBO + low dose cytarabine
    Interventions:
    • Drug: placebo
    • Drug: low dose cytarabine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
660
January 2016
January 2016   (final data collection date for primary outcome measure)

Inclusion criteria:

  1. Age >= 65years.
  2. Cytologically/histologically confirmed acute myeloid leukaemia (AML) according to WHO classification; (except for acute promyelocytic leukaemia (APL).
  3. Previously untreated AML (except for hydroxyurea and/or corticosteroid therapy for no more than 28 days (cumulative)). Previous therapy for Myelodysplastic Syndrome (MDS) is allowed.
  4. Investigator considers patient ineligible for intensive remission induction therapy based on documented medical reasons (e.g. disease characteristics like AML genetics, type of AML (de novo or secondary), and patient characteristics like performance score, concomitant diagnoses, organ dysfunctions).
  5. Patient is eligible for Low-Dose Cytarabine (LDAC) treatment.
  6. Eastern co-operative oncology group (ECOG) performance score <= 2 at screening.
  7. Signed and dated written informed consent by start date of Screening visit in accordance with Good Clinical Practice (GCP) and local legislation.

Exclusion criteria:

  1. Prior or concomitant chemotherapy for AML (with the exception of hydroxyurea and/or corticosteroid therapy for no more than 28 days (cumulative)). Please note that any prior therapy for MDS is allowed.
  2. Treatment with any investigational drug within 2 weeks before first administration of present trial drug.
  3. Acute promyelocytic leukaemia (French-American-British (FAB) classification subtype M3).
  4. Current clinical central nervous system (CNS) symptoms deemed by the investigator to be related to leukaemic CNS involvement (no lumbar puncture required, clinical assessment per investigator´s judgement is sufficient).
  5. Hypersensitivity to one of the trial drugs or the excipients.
  6. Severe illness or organ dysfunction involving the heart, kidney, liver or other organ system (e.g. active infection, clinically relevant impairment of cardiac function, severe heart failure/cardiac insufficiency, unstable angina pectoris or history of recent myocardial infarction), which in the opinion of the investigator precludes treatment with LDAC.
  7. Corrected QT interval according to Fridericia (QTcF) prolongation > 470 ms or QT prolongation deemed clinically relevant by the investigator (e.g., congenital long QT syndrome).The QTcF will be calculated as the mean of the 3 Electrocardiogram (ECGs) taken at screening.
  8. Total bilirubin > 3 x upper limit of normal (ULN).
  9. Creatinine clearance (CLcr) < 30 ml/min (estimated creatinine clearance by the Cockcroft-Gault (C-G) equation) .
  10. Active hepatitis B or hepatitis C, or laboratory evidence for a chronic infection.
  11. HIV infection.
  12. Second malignancy currently requiring active therapy (except for hormonal/anti-hormonal treatment e.g. in prostate or breast cancer).
  13. Any significant concurrent psychiatric disorder or social situation that according to the investigator´s judgement would compromise patient´s safety or compliance, interfere with consent, study participation, or interpretation of study results.
  14. Known or suspected active alcohol or drug abuse.
  15. Patient unable to comply with the protocol, in the opinion of the investigator.
  16. Male patients with partners of childbearing potential who are unwilling to use condoms in combination with a second medically acceptable method of contraception during the trial and for a minimum of 6 months after study treatment.
Both
Not Provided
No
Contact: Boehringer Ingelheim Call Center 1-800-243-0127 clintriage.rdg@boehringer-ingelheim.com
United States,   Argentina,   Austria,   Belgium,   Brazil,   Canada,   Czech Republic,   Finland,   France,   Germany,   Greece,   Hungary,   India,   Italy,   Japan,   Korea, Republic of,   Mexico,   Netherlands,   Norway,   Poland,   Portugal,   Russian Federation,   South Africa,   Spain,   Taiwan
 
NCT01721876
1230.14, 2012-002487-27
Not Provided
Boehringer Ingelheim
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Boehringer Ingelheim
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP